PCS-499

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
PCS-499
Accession Number
DB15122
Type
Small Molecule
Groups
Investigational
Description

PCS-499 is under investigation in clinical trial NCT01487109 (A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients).

Structure
Thumb
Synonyms
Not Available
External IDs
CTP-499
Categories
UNII
FLV771E8ZV
CAS number
1268605-91-9
Weight
Average: 285.359
Monoisotopic: 285.18492425
Chemical Formula
C13H20N4O3
InChI Key
NSMXQKNUPPXBRG-WHPHVCHMSA-N
InChI
InChI=1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8-9,18H,4-7H2,1-3H3/t9-/m0/s1/i1D3,6D2
IUPAC Name
1-[(5S)-5-hydroxy(4,4,6,6,6-2H5)hexyl]-3,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione
SMILES
[2H]C([2H])([2H])[C@H](O)C([2H])([2H])CCCN1C(=O)N(C)C2=C(N(C)C=N2)C1=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with PCS-499.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with PCS-499.
3,5-Diiodotyrosine3,5-Diiodotyrosine may decrease the excretion rate of PCS-499 which could result in a higher serum level.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with PCS-499.
6-Deoxyerythronolide BThe metabolism of PCS-499 can be decreased when combined with 6-Deoxyerythronolide B.
7-Nitroindazole7-Nitroindazole may increase the excretion rate of PCS-499 which could result in a lower serum level and potentially a reduction in efficacy.
AbirateroneThe serum concentration of PCS-499 can be increased when it is combined with Abiraterone.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with PCS-499.
AcetazolamideAcetazolamide may increase the excretion rate of PCS-499 which could result in a lower serum level and potentially a reduction in efficacy.
AdalimumabThe serum concentration of PCS-499 can be decreased when it is combined with Adalimumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
64854385

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentDiabetic Nephropathies1
1CompletedTreatmentStage 3 Chronic Kidney Disease1
2CompletedTreatmentChronic Kidney Disease (CKD) / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility7.76 mg/mLALOGPS
logP0.78ALOGPS
logP0.2ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)17.68ChemAxon
pKa (Strongest Basic)-1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area78.67 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity74.65 m3·mol-1ChemAxon
Polarizability30.03 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:51 / Updated on November 02, 2019 03:30